New hope for tough cancers: First-of-its-Kind antibody trial targets common growth signal
NCT ID NCT07292168
Summary
This study is testing a new antibody drug called OM-RCA-01 in people with advanced cancers that have spread and have a specific protein (FGFR1). The main goals are to find a safe dose and see if the drug can slow down tumor growth. About 58 people with certain types of metastatic cancer (kidney, lung, prostate, breast, or head & neck) who have already tried standard treatments will receive the drug through an IV every two weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center
RECRUITINGKrasnoyarsk, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hadassah Medical
RECRUITINGMoscow, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
I.P. Pavlov First Saint Petersburg State Medical University
RECRUITINGSaint Petersburg, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Republican Clinical Oncology Dispensary
RECRUITINGUfa, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Republican Dispensary of Tatarstan
ACTIVE_NOT_RECRUITINGKazan', Russia
Conditions
Explore the condition pages connected to this study.